Bank of America Securities analyst Tim Anderson has maintained their neutral stance on PFE stock, giving a Hold rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tim Anderson has given his Hold rating due to a combination of factors related to Pfizer’s strategic moves and financial outlook. The acquisition of Metsera (MTSR) by Pfizer is a significant step towards entering the obesity market, which is seen as a positive development. However, the full potential of this acquisition is contingent upon various pipeline-related milestones, and the deal is still subject to shareholder approval and other conditions.
Despite the promising acquisition, Tim Anderson maintains a Neutral rating on Pfizer due to concerns about the long-term growth prospects of its larger franchises. These concerns are primarily driven by upcoming patent expirations and competitive pressures, which could impact Pfizer’s growth trajectory. Additionally, while Pfizer’s current price-to-earnings ratio and dividend yield provide some support to its stock price, they are not sufficient to warrant a more bullish outlook given the uncertainties ahead.
In another report released yesterday, Bernstein also reiterated a Hold rating on the stock with a $30.00 price target.